Sagimet Biosciences has filed a notice of an Initial Public Offering of securities to raise $85,000,000.00 in new Equity.
According to filings with the U.S. Securities and Exchange Commission, Sagimet Biosciences is raising $85,000,000.00 in new funding. About Sagimet Biosciences: Sagimet is developing a portfolio of novel therapeutics called fatty acid synthase (FASN) inhibitors…